Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000075.xml
Download PDF
Semin Respir Crit Care Med 2025; 46(01): 041-052
DOI: 10.1055/a-2586-3974
DOI: 10.1055/a-2586-3974
Review Article
Respiratory Syncytial Virus Prevention in the Adult Population: State of the Art
Funding None.
Abstract
Respiratory syncytial virus (RSV) is a common respiratory virus associated with acute respiratory infections (ARIs) in infants and older adults. RSV-related ARIs significantly affect the relevant clinical outcomes, including hospitalization and mortality, in older adults. Elderly individuals and those with chronic diseases are at a higher risk of infections with severe morbidity because of clinical frailty and deficiencies in immune responses. Prevention of respiratory viral infections in the adult population can be achieved through hygiene measures and active immunization. Several vaccination strategies have been developed, including nucleic acid, subunit, chimeric, live-attenuated, particle-based, and recombinant vaccines, with varying results. Subunit vaccines involving the RSV-fusion protein F in its prefusional (pre-F) conformation, with or without adjuvants, have demonstrated significant protection in older adults, reducing the rate of total and severe RSV-related lower tract respiratory diseases (LRTDs). Similarly, an mRNA vaccine encoding for the stabilized pre-F conformation showed a significantly reduced RSV-associated LRTDs in older adults. This evidence led to recent approval of two subunit vaccines (Arexvy and Abrysvo) and one nucleic acid-based vaccine (mResvia) by regulatory authorities. Currently, several vaccines are recommended for adults, resulting in crowded schedules. Therefore, covaccination is a potential strategy for improving vaccine adherence. The coadministration of approved RSV vaccines with seasonal influenza vaccines has been proven to be non-inferior to the immune response from sequential administration. Other vaccines coadministered against different pathogens are currently under investigation.
Publication History
Article published online:
06 June 2025
© 2025. Thieme. All rights reserved.
Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA
-
References
- 1 Duan Y, Jiang M, Huang Q, Jia M, Yang W, Feng L. Incidence, hospitalization, and mortality in children aged 5 years and younger with respiratory syncytial virus-related diseases: a systematic review and meta-analysis. Influenza Other Respir Viruses 2023; 17 (05) e13145
- 2 Cong B, Dighero I, Zhang T, Chung A, Nair H, Li Y. Understanding the age spectrum of respiratory syncytial virus associated hospitalisation and mortality burden based on statistical modelling methods: a systematic analysis. BMC Med 2023; 21 (01) 224
- 3 Falsey AR, Walsh EE, Esser MT, Shoemaker K, Yu L, Griffin MP. Respiratory syncytial virus-associated illness in adults with advanced chronic obstructive pulmonary disease and/or congestive heart failure. J Med Virol 2019; 91 (01) 65-71
- 4 Shi T, Vennard S, Jasiewicz F, Brogden R, Nair H. RESCEU Investigators. Disease burden estimates of respiratory syncytial virus related acute respiratory infections in adultswith comorbidity: a systematic review and meta-analysis. J Infect Dis 2022; 226 (suppl 1): S17-S21
- 5 Abrysvo | European Medicines Agency (EMA). September 15, 2023. Accessed December 19, 2024 at: https://www.ema.europa.eu/en/medicines/human/EPAR/abrysvo
- 6 Arexvy | European Medicines Agency (EMA). June 16, 2023. Accessed December 19, 2024 at: https://www.ema.europa.eu/en/medicines/human/EPAR/arexvy
- 7 mResvia | European Medicines Agency (EMA). September 6, 2024. Accessed December 19, 2024 at: https://www.ema.europa.eu/en/medicines/human/EPAR/mresvia
- 8 Center for Biologics Evaluation and Research. MRESVIA. FDA. Published online April 10, 2024. Accessed December 19, 2024 at: https://www.fda.gov/vaccines-blood-biologics/vaccines/mresvia
- 9 Center for Biologics Evaluation and Research. ABRYSVO. FDA. Published online October 23, 2024. Accessed December 19, 2024 at: https://www.fda.gov/vaccines-blood-biologics/abrysvo
- 10 Center for Biologics Evaluation and Research. AREXVY. FDA. Published online August 22, 2024. Accessed December 19, 2024 at: https://www.fda.gov/vaccines-blood-biologics/arexvy
- 11 Kelleher K, Subramaniam N, Drysdale SB. The recent landscape of RSV vaccine research. Ther Adv Vaccines Immunother 2025; 13:25151355241310601
- 12 Nam HH, Ison MG. Respiratory syncytial virus infection in adults. BMJ 2019; 366: l5021
- 13 Simões EAF. RSV disease in the pediatric population: epidemiology, seasonal variability, and long-term outcomes. Manag Care 2008; 17 (11, suppl 12): 3-6 , discussion 18–19
- 14 Kenmoe S, Nair H. The disease burden of respiratory syncytial virus in older adults. Curr Opin Infect Dis 2024; 37 (02) 129-136
- 15 Njue A, Nuabor W, Lyall M. et al. Systematic literature review of risk factors for poor outcomes among adults with respiratory syncytial virus infection in high-income countries. Open Forum Infect Dis 2023; 10 (11) ofad513
- 16 Bergeron HC, Tripp RA. Immunopathology of RSV: an updated review. Viruses 2021; 13 (12) 2478
- 17 Agac A, Kolbe SM, Ludlow M, Osterhaus ADME, Meineke R, Rimmelzwaan GF. Host responses to respiratory syncytial virus infection. Viruses 2023; 15 (10) 1999
- 18 Johnson PR, Spriggs MK, Olmsted RA, Collins PL. The G glycoprotein of human respiratory syncytial viruses of subgroups A and B: extensive sequence divergence between antigenically related proteins. Proc Natl Acad Sci U S A 1987; 84 (16) 5625-5629
- 19 Crooke SN, Ovsyannikova IG, Poland GA, Kennedy RB. Immunosenescence and human vaccine immune responses. Immun Ageing 2019; 16: 25
- 20 Jumat MR, Yan Y, Ravi LI. et al. Morphogenesis of respiratory syncytial virus in human primary nasal ciliated epithelial cells occurs at surface membrane microdomains that are distinct from cilia. Virology 2015; 484: 395-411
- 21 Morton CJ, Cameron R, Lawrence LJ. et al. Structural characterization of respiratory syncytial virus fusion inhibitor escape mutants: homology model of the F protein and a syncytium formation assay. Virology 2003; 311 (02) 275-288
- 22 König P, Giesow K, Schuldt K, Buchholz UJ, Keil GM. A novel protein expression strategy using recombinant bovine respiratory syncytial virus (BRSV): modifications of the peptide sequence between the two furin cleavage sites of the BRSV fusion protein yield secreted proteins, but affect processing and function of the BRSV fusion protein. J Gen Virol 2004; 85 (Pt 7): 1815-1824
- 23 Schlender J, Zimmer G, Herrler G, Conzelmann KK. Respiratory syncytial virus (RSV) fusion protein subunit F2, not attachment protein G, determines the specificity of RSV infection. J Virol 2003; 77 (08) 4609-4616
- 24 Chatterjee M, van Putten JPM, Strijbis K. Defensive properties of mucin glycoproteins during respiratory infections—relevance for SARS-CoV-2. MBio 2020; 11 (06) e02374-20
- 25 Bailey KL. Aging diminishes mucociliary clearance of the lung. Adv Geriatr Med Res 2022; 4 (02) x
- 26 Branche AR, Saiman L, Walsh EE. et al. Incidence of respiratory syncytial virus infection among hospitalized adults, 2017-2020. Clin Infect Dis 2022; 74 (06) 1004-1011
- 27 CDC. RSV in Older Adults. Respiratory Syncytial Virus Infection (RSV). December 3, 2024. Accessed March 11, 2025 at: https://www.cdc.gov/rsv/older-adults/index.html
- 28 Falsey AR, Formica MA, Hennessey PA, Criddle MM, Sullender WM, Walsh EE. Detection of respiratory syncytial virus in adults with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006; 173 (06) 639-643
- 29 Kaler J, Hussain A, Patel K, Hernandez T, Ray S. Respiratory syncytial virus: a comprehensive review of transmission, pathophysiology, and manifestation. Cureus 2023; 15 (03) e36342
- 30 Respiratory syncytial virus (RSV). Accessed March 11, 2025 at: https://www.who.int/news-room/fact-sheets/detail/respiratory-syncytial-virus-(rsv)
- 31 Chatzis O, Darbre S, Pasquier J. et al. Burden of severe RSV disease among immunocompromised children and adults: a 10 year retrospective study. BMC Infect Dis 2018; 18 (01) 111
- 32 Lee N, Lui GCY, Wong KT. et al. High morbidity and mortality in adults hospitalized for respiratory syncytial virus infections. Clin Infect Dis 2013; 57 (08) 1069-1077
- 33 Onwuchekwa C, Moreo LM, Menon S. et al. Underascertainment of respiratory syncytial virus infection in adults due to diagnostic testing limitations: a systematic literature review and meta-analysis. J Infect Dis 2023; 228 (02) 173-184
- 34 Popow-Kraupp T, Aberle JH. Diagnosis of respiratory syncytial virus infection. Open Microbiol J 2011; 5: 128-134
- 35 Chartrand C, Tremblay N, Renaud C, Papenburg J. Diagnostic accuracy of rapid antigen detection tests for respiratory syncytial virus infection: systematic review and meta-analysis. J Clin Microbiol 2015; 53 (12) 3738-3749
- 36 Falsey AR, Walsh EE. Respiratory syncytial virus infection in adults. Clin Microbiol Rev 2000; 13 (03) 371-384
- 37 Olsen SJ, Winn AK, Budd AP. et al. Changes in influenza and other respiratory virus activity during the COVID-19 pandemic—United States, 2020-2021. MMWR Morb Mortal Wkly Rep 2021; 70 (29) 1013-1019
- 38 Centre for Health Protection. Department of Health - Respiratory Syncytial Virus Infection. Accessed October 10, 2024 at: https://www.chp.gov.hk/en/healthtopics/content/24/36.html
- 39 Vijh R, Prairie J, Otterstatter MC. et al. Evaluation of a multisectoral intervention to mitigate the risk of severe acute respiratory coronavirus virus 2 (SARS-CoV-2) transmission in long-term care facilities. Infect Control Hosp Epidemiol 2021; 42 (10) 1181-1188
- 40 Vetter V, Denizer G, Friedland LR, Krishnan J, Shapiro M. Understanding modern-day vaccines: what you need to know. Ann Med 2018; 50 (02) 110-120
- 41 Hellgren F, Rosdahl A, Arcoverde Cerveira R. et al. Modulation of innate immune response to mRNA vaccination after SARS-CoV-2 infection or sequential vaccination in humans. JCI Insight 2024; 9 (09) e175401
- 42 Clem AS. Fundamentals of vaccine immunology. J Glob Infect Dis 2011; 3 (01) 73-78
- 43 Acosta PL, Caballero MT, Polack FP. Brief history and characterization of enhanced respiratory syncytial virus disease. Clin Vaccine Immunol 2015; 23 (03) 189-195
- 44 RSV vaccine and mAb snapshot. Accessed April 4, 2025 at: https://www.path.org/our-impact/resources/rsv-vaccine-and-mab-snapshot/
- 45 Topalidou X, Kalergis AM, Papazisis G. Respiratory syncytial virus vaccines: a review of the candidates and the approved vaccines. Pathogens 2023; 12 (10) 1259
- 46 Boyoglu-Barnum S, Chirkova T, Anderson LJ. Biology of infection and disease pathogenesis to guide RSV vaccine development. Front Immunol 2019; 10: 1675
- 47 Crank MC, Ruckwardt TJ, Chen M. et al; VRC 317 Study Team. A proof of concept for structure-based vaccine design targeting RSV in humans. Science 2019; 365 (6452): 505-509
- 48 Chang LA, Phung E, Crank MC. et al. A prefusion-stabilized RSV F subunit vaccine elicits B cell responses with greater breadth and potency than a postfusion F vaccine. Sci Transl Med 2022; 14 (676) eade0424
- 49 Papi A, Ison MG, Langley JM. et al; AReSVi-006 Study Group. Respiratory syncytial virus prefusion F protein vaccine in older adults. N Engl J Med 2023; 388 (07) 595-608
- 50 Ison MG, Papi A, Athan E. et al; AReSVi-006 Study Group. Efficacy and safety of respiratory syncytial virus (RSV) prefusion F protein vaccine (RSVPreF3 OA) in older adults over 2 RSV seasons. Clin Infect Dis 2024; 78 (06) 1732-1744
- 51 Ison MG, Papi A, Athan E. et al; AReSVi-006 study group.. Efficacy, safety, and immunogenicity of the AS01E-adjuvanted respiratory syncytial virus prefusion F protein vaccine (RSVPreF3 OA) in older adults over three respiratory syncytial virus seasons (AReSVi-006): a multicentre, randomised, observer-blinded, placebo-controlled, phase 3 trial. Lancet Respir Med 2025; 11: S2213-2600 (25)00048-7
- 52 Ison MG, Papi A, Athan E. et al, on behalf of the AReSVi-006 study group.. The Efficacy of a Single Dose of the Respiratory Syncytial Virus Prefusion F Protein Vaccine in Adults ≥60 Years of Age Over 3 RSV Seasons. Poster 3391 presented at CHEST 2024 – (2024 October 6-9), Boston, United States
- 53 Walsh EE, Pérez Marc G, Zareba AM. et al; RENOIR Clinical Trial Group. Efficacy and safety of a bivalent RSV prefusion F vaccine in older adults. N Engl J Med 2023; 388 (16) 1465-1477
- 54 Kampmann B, Madhi SA, Munjal I. et al; MATISSE Study Group. Bivalent prefusion F vaccine in pregnancy to prevent RSV illness in infants. N Engl J Med 2023; 388 (16) 1451-1464
- 55 Walsh EE, Pérez Marc G, Falsey AR. et al. RENOIR trial—RSVpreF vaccine efficacy over two seasons. N Engl J Med 2024; 391 (15) 1459-1460
- 56 Commissioner O of the. FDA Requires Guillain-Barré Syndrome (GBS) Warning in the Prescribing Information for RSV Vaccines Abrysvo and Arexvy: FDA Safety Communication. FDA. Published online July 1, 2025. Accessed March 26, 2025 at: https://www.fda.gov/safety/medical-product-safety-information/fda-requires-guillain-barre-syndrome-gbs-warning-prescribing-information-rsv-vaccines-abrysvo-and
- 57 2024 GINA Main Report. Global Initiative for Asthma - GINA. Accessed December 19, 2024 at: https://ginasthma.org/2024-report/
- 58 2024 GOLD Report. Global Initiative for Chronic Obstructive Lung Disease - GOLD. Accessed December 19, 2024 at: https://goldcopd.org/2024-gold-report/
- 59 Respiratory Syncytial Virus (RSV). FDA. Published online October 25, 2024. Accessed December 19, 2024 at: https://www.fda.gov/consumers/covid-19-flu-and-rsv/respiratory-syncytial-virus-rsv
- 60 Fan YJ, Chan KH, Hung IFN. Safety and efficacy of COVID-19 vaccines: a systematic review and meta-analysis of different vaccines at phase 3. Vaccines (Basel) 2021; 9 (09) 989
- 61 Geall AJ, Verma A, Otten GR. et al. Nonviral delivery of self-amplifying RNA vaccines. Proc Natl Acad Sci U S A 2012; 109 (36) 14604-14609
- 62 Mazur NI, Terstappen J, Baral R. et al. Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscape. Lancet Infect Dis 2023; 23 (01) e2-e21
- 63 Lu RM, Hsu HE, Perez SJLP. et al. Current landscape of mRNA technologies and delivery systems for new modality therapeutics. J Biomed Sci 2024; 31 (01) 89
- 64 Baden LR, El Sahly HM, Essink B. et al; COVE Study Group. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 2021; 384 (05) 403-416
- 65 Moderna Announces Updates on Respiratory Syncytial Virus (RSV) Vaccine Program. Accessed March 26, 2025 at: https://investors.modernatx.com/news/news-details/2020/Moderna-Announces-Updates-on-Respiratory-Syncytial-Virus-RSV-Vaccine-Program/default.aspx
- 66 Li J, Long H, Chen S. et al. An mRNA-based respiratory syncytial virus vaccine elicits strong neutralizing antibody responses and protects rodents without vaccine-associated enhanced respiratory disease. Vaccines (Basel) 2025; 13 (01) 52
- 67 Smith TRF, Schultheis K, Broderick KE. Nucleic acid-based vaccines targeting respiratory syncytial virus: delivering the goods. Hum Vaccin Immunother 2017; 13 (11) 2626-2629
- 68 Qiu X, Xu S, Lu Y. et al. Development of mRNA vaccines against respiratory syncytial virus (RSV). Cytokine Growth Factor Rev 2022; 68: 37-53
- 69 Wilson E, Goswami J, Baqui AH. et al; ConquerRSV Study Group. Efficacy and safety of an mRNA-based RSV PreF vaccine in older adults. N Engl J Med 2023; 389 (24) 2233-2244
- 70 Shaw CA, Mithani R, Kapoor A. et al. Safety, tolerability, and immunogenicity of an mRNA-based respiratory syncytial virus vaccine in healthy young adults in a phase 1 clinical trial. J Infect Dis 2024; 230 (03) e637-e646
- 71 Andreoni M, Bonanni P, Gabutti G, Maggi S, Siliquini R, Ungar A. RSV vaccination as the optimal prevention strategy for older adults. Infez Med 2024; 32 (04) 478-488
- 72 Peng R, Chen C, Chen Q. et al. Global progress in clinical research on human respiratory syncytial virus vaccines. Front Microbiol 2024; 15: 1457703
- 73 Yonts AB, Gaviria-Agudelo C, Kimberlin DW, Paulsen GC, O'Leary ST. June 2024 ACIP meeting update: influenza, COVID-19, RSV, and other vaccines. Pediatrics 2024; 154 (04) e2024068310
- 74 Update on Moderna's RSV vaccine, mRESVIA (mRNA-1345), in adults ≥60 years of age. Accessed May 20, 2025 at: https://www.cdc.gov/acip/downloads/slides-2024-06-26-28/04-RSV-Adult-Das-508.pdf
- 75 Nooraei S, Bahrulolum H, Hoseini ZS. et al. Virus-like particles: preparation, immunogenicity and their roles as nanovaccines and drug nanocarriers. J Nanobiotechnology 2021; 19 (01) 59
- 76 Schaerlaekens S, Jacobs L, Stobbelaar K, Cos P, Delputte P. All eyes on the prefusion-stabilized F construct, but are we missing the potential of alternative targets for respiratory syncytial virus vaccine design?. Vaccines (Basel) 2024; 12 (01) 97
- 77 Widmer K, Griffin MR, Zhu Y, Williams JV, Talbot HK. Respiratory syncytial virus- and human metapneumovirus-associated emergency department and hospital burden in adults. Influenza Other Respir Viruses 2014; 8 (03) 347-352
- 78 Shapiro C, Sánchez-Crespo N, Ciarlet M. et al. A randomized phase 1 clinical trial of a respiratory syncytial virus and human metapneumovirus combination protein-based virus-like particle vaccine in adults 60 to 75 years of age. Open Forum Infect Dis 2025; 12 (04) ofaf160
- 79 Hervé PL, Dhelft V, Zuniga A. et al. Epicutaneous immunization using synthetic virus-like particles efficiently boosts protective immunity to respiratory syncytial virus. Vaccine 2021; 39 (32) 4555-4563
- 80 Leroux-Roels I, Bruhwyler J, Stergiou L. et al. Double-blind, placebo-controlled, dose-escalating study evaluating the safety and immunogenicity of an epitope-specific chemically defined nanoparticle RSV vaccine. Vaccines (Basel) 2023; 11 (02) 367
- 81 Abarca K, Rey-Jurado E, Muñoz-Durango N. et al. Safety and immunogenicity evaluation of recombinant BCG vaccine against respiratory syncytial virus in a randomized, double-blind, placebo-controlled phase I clinical trial. EClinicalMedicine 2020; 27: 100517
- 82 Scaggs Huang F, Bernstein DI, Slobod KS. et al. Safety and immunogenicity of an intranasal sendai virus-based vaccine for human parainfluenza virus type I and respiratory syncytial virus (SeVRSV) in adults. Hum Vaccin Immunother 2021; 17 (02) 554-559
- 83 Cunningham CK, Karron RA, Muresan P. et al; International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) 2018 Study Team. Evaluation of recombinant live-attenuated respiratory syncytial virus (RSV) vaccines RSV/ΔNS2/Δ1313/I1314L and RSV/276 in RSV-seronegative children. J Infect Dis 2022; 226 (12) 2069-2078
- 84 Wang S, Liang B, Wang W. et al. Viral vectored vaccines: design, development, preventive and therapeutic applications in human diseases. Signal Transduct Target Ther 2023; 8 (01) 149
- 85 Samy N, Reichhardt D, Schmidt D. et al. Safety and immunogenicity of novel modified vaccinia Ankara-vectored RSV vaccine: a randomized phase I clinical trial. Vaccine 2020; 38 (11) 2608-2619
- 86 Jordan E, Lawrence SJ, Meyer TPH. et al. Broad antibody and cellular immune response from a phase 2 clinical trial with a novel multivalent poxvirus-based respiratory syncytial virus vaccine. J Infect Dis 2021; 223 (06) 1062-1072
- 87 Jordan E, Jenkins V, Silbernagl G. et al. A multivalent RSV vaccine based on the modified vaccinia Ankara vector shows moderate protection against disease caused by RSV in older adults in a phase 3 clinical study. Vaccine 2024; 42 (26) 126427
- 88 Stuart ASV, Virta M, Williams K. et al. Phase 1/2a safety and immunogenicity of an adenovirus 26 vector respiratory syncytial virus (RSV) vaccine encoding prefusion F in adults 18-50 years and RSV-seropositive children 12-24 months. J Infect Dis 2022; 227 (01) 71-82
- 89 Saeland E, van der Fits L, Bolder R. et al. Immunogenicity and protective efficacy of adenoviral and subunit RSV vaccines based on stabilized prefusion F protein in pre-clinical models. Vaccine 2022; 40 (06) 934-944
- 90 van der Fits L, Bolder R, Heemskerk-van der Meer M. et al. Adenovector 26 encoded prefusion conformation stabilized RSV-F protein induces long-lasting Th1-biased immunity in neonatal mice. NPJ Vaccines 2020; 5 (01) 49
- 91 Langley JM, Nolan TM, Rämet M. et al. A phase 1/2a study evaluating safety and immunogenicity of Ad26.RSV.preF in RSV-seronegative toddlers aged 12-24 months. Open Forum Infect Dis 2024; 11 (09) ofae453
- 92 Williams K, Bastian AR, Feldman RA. et al. Phase 1 safety and immunogenicity study of a respiratory syncytial virus vaccine with an adenovirus 26 vector encoding prefusion F (Ad26.RSV.preF) in adults aged ≥60 years. J Infect Dis 2020; 222 (06) 979-988
- 93 Sadoff J, De Paepe E, DeVincenzo J. et al. Prevention of respiratory syncytial virus infection in healthy adults by a single immunization of Ad26.RSV.preF in a human challenge study. J Infect Dis 2022; 226 (03) 396-406
- 94 Eto T, Okubo Y, Momose A. et al. A randomized, double-blind, placebo-controlled, phase 1 study to evaluate the safety, reactogenicity, and immunogenicity of single vaccination of Ad26.RSV.preF-based regimen in Japanese adults aged 60 years and older. Influenza Other Respir Viruses 2024; 18 (06) e13336
- 95 Widagdo W, Bastian AR, Jastorff AM. et al. Concomitant administration of Ad26.RSV.preF/RSV preF protein vaccine and high-dose influenza vaccine in adults 65 years and older: a noninferiority trial. J Infect Dis 2024; 230 (02) e374-e383
- 96 Falsey AR, Williams K, Gymnopoulou E. et al; CYPRESS Investigators. Efficacy and safety of an Ad26.RSV.preF-RSV preF protein vaccine in older adults. N Engl J Med 2023; 388 (07) 609-620
- 97 Falsey AR, Hosman T, Bastian AR. et al; CYPRESS investigators. Long-term efficacy and immunogenicity of Ad26.RSV.preF-RSV preF protein vaccine (CYPRESS): a randomised, double-blind, placebo-controlled, phase 2b study. Lancet Infect Dis 2024; 24 (09) 1015-1024
- 98 Johnson & Johnson Discontinues Phase 3 Study Evaluating Respiratory Syncytial Virus Vaccine. Pharmacy Times. March 30, 2023. Accessed March 11, 2025 at: https://www.pharmacytimes.com/view/johnson-johnson-discontinues-phase-3-study-evaluating-respiratory-syncytial-virus-vaccine
- 99 Gross National Income for Middle Income Countries. December 17, 2024. Accessed December 19, 2024 at: https://fred.stlouisfed.org/series/NYGNPMKTPCDMIC
- 100 Li Y, Wang X, Blau DM. et al; Respiratory Virus Global Epidemiology Network, RESCEU investigators. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis. Lancet 2022; 399 (10340): 2047-2064
- 101 Lancet T. The Lancet. Making more of multimorbidity: an emerging priority. Lancet 2018; 391 (10131): 1637
- 102 Basto-Abreu A, Barrientos-Gutierrez T, Wade AN. et al. Multimorbidity matters in low and middle-income countries. J Multimorb Comorb 2022;12:26335565221106074
- 103 Fitzpatrick MC, Laufer RS, Baral R. et al. Report of the WHO technical consultation on the evaluation of respiratory syncytial virus prevention cost effectiveness in low- and middle-income countries, April 7-8, 2022. Vaccine 2023; 41 (48) 7047-7059
- 104 Zar HJ, Madhi SA, Aston SJ, Gordon SB. Pneumonia in low and middle income countries: progress and challenges. Thorax 2013; 68 (11) 1052-1056
- 105 Global Burden of Diseases in Low and Middle Income Countries. October 25, 2024. Accessed December 12, 2025 at: https://www.europarl.europa.eu/cmsdata/130573/Khassoum%20Diallo.pdf
- 106 Bonanni P, Bonaccorsi G, Lorini C. et al. Focusing on the implementation of 21st century vaccines for adults. Vaccine 2018; 36 (36) 5358-5365
- 107 Bonanni P, Steffen R, Schelling J. et al. Vaccine coadministration in adults: an effective way to improve vaccination coverage. Hum Vaccin Immunother 2023; 19 (01) 2195786
- 108 Maggi S, Launay O, Dawson R. Respiratory virus vaccines: pathways to recommendations and enhanced coverage for at-risk populations. Infect Dis Ther 2025; 14 (1, suppl 1): 99-114
- 109 Debbag R, Rudin D, Ceddia F, Watkins J. The impact of vaccination on COVID-19, influenza, and respiratory syncytial virus-related outcomes: a narrative review. Infect Dis Ther 2025; 14 (Suppl. 01) 63-97
- 110 Chandler R, Montenegro N, Llorach C. et al. Immunogenicity, reactogenicity, and safety of AS01E-adjuvanted RSV prefusion F protein-based candidate vaccine (RSVPreF3 OA) when coadministered with a seasonal quadrivalent influenza vaccine in older adults: results of a phase 3, open-label, randomized controlled trial. Clin Infect Dis 2024; x: 786
- 111 Falsey AR, Walsh EE, Scott DA. et al. Phase 1/2 randomized study of the immunogenicity, safety, and tolerability of a respiratory syncytial virus prefusion F vaccine in adults with concomitant inactivated influenza vaccine. J Infect Dis 2022; 225 (12) 2056-2066
- 112 Athan E, Baber J, Quan K. et al; Study C3671006 Investigator Group. Safety and immunogenicity of bivalent RSVpreF vaccine coadministered with seasonal inactivated influenza vaccine in older adults. Clin Infect Dis 2024; 78 (05) 1360-1368
- 113 Goswami J, Cardona JF, Hsu DC. et al. Safety and immunogenicity of mRNA-1345 RSV vaccine coadministered with an influenza or COVID-19 vaccine in adults aged 50 years or older: an observer-blinded, placebo-controlled, randomised, phase 3 trial. Lancet Infect Dis 2024; 25 (04) 411-423
- 114 Surie D, Self WH, Zhu Y. et al; Investigating Respiratory Viruses in the Acutely Ill (IVY) Network. RSV vaccine effectiveness against hospitalization among US adults 60 years and older. JAMA 2024; 332 (13) 1105-1107
- 115 Payne AB, Watts JA, Mitchell PK. et al. Respiratory syncytial virus (RSV) vaccine effectiveness against RSV-associated hospitalisations and emergency department encounters among adults aged 60 years and older in the USA, October, 2023, to March, 2024: a test-negative design analysis. Lancet 2024; 404 (10462): 1547-1559